Professor Adil Mardinoglu works as a Professor of Systems Biology at the Centre for Host-Microbiome Interactions at King’s College London, UK, and Science for Life Laboratory (SciLifeLab) at KTH-Royal Institute of Technology in Sweden. At the helm of a 25-strong research team, Professor Mardinoglu spearheads the development of novel treatment strategies for metabolic and neurodegenerative diseases, as well as certain cancers, blending multiomics, systems biology, AI and drug development.

A key contributor to the Swedish Human Protein Atlas program, Professor Mardinoglu has aided in the construction of a comprehensive human tissue, single cell, subcellular, blood and pathology atlas. His scholarly output includes more than 250 research and review articles published in journals such as Science, Nature, Nature Biotechnology, Cell Metabolism, Nature Metabolism, Nature Communications, PNAS, Cell Reports, Molecular Systems Biology, and EbioMedicine. Furthermore, as a co-founder of SZA Longevity, Trustlife Therapeutics, ScandiBio Therapeutics and ScandiEdge Therapeutics, he has made substantial entrepreneurial contributions to the biotech sector.